Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00921206 · ClinicalTrials.gov registry record · Phase 1
Study to Investigate the Immune Response to Two Doses of VAX102 Healthy Adults
A Phase 1 study, sponsored by VaxInnate Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT00921206 is a Phase 1 study that has completed, run by VaxInnate Corporation. The registered enrollment target is 21 participants.
The verdict
NCT00921206, a Phase 1 study, has completed, sponsored by VaxInnate Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The objective is to assess the humoral and cellular immune response of the VAX102 vaccine delivered IM and SC in a prime-boost regimen at dose levels 1 µg or 2 µg in healthy adults against the influenza A virus M2e antigen after each vaccination.
Interventions
- BIOLOGICAL VAX102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2009-06 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00921206
The ClinicalTrials.gov registry entry for NCT00921206 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VaxInnate Corporation, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VAX102 is the first listed.
NCT00921206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00921206 about?
NCT00921206 is a clinical study titled "Study to Investigate the Immune Response to Two Doses of VAX102 Healthy Adults". The objective is to assess the humoral and cellular immune response of the VAX102 vaccine delivered IM and SC in a prime-boost regimen at dose levels 1 µg or 2 µg in healthy adults against the influenza A virus M2e antigen after each vaccination.
What is the current status of trial NCT00921206?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2009-06. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00921206?
The interventions under investigation include: VAX102 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00921206?
This trial is sponsored by VaxInnate Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.